The Boardroom Battle at Intel Cost Me Money and Changed How I Vote Proxies

why I bought Intel in the first place

I purchased 600 shares of Intel at an average price of $24.80 between October 2024 and March 2025. The thesis was simple and, in retrospect, deeply flawed. Intel was trading at a cyclical low. The fresh CEO, Pat Gelsinger, had announced a foundry services strategy that would turn Intel into a contract chip manufacturer competing directly with TSMC. The U.S. government had awarded Intel $8.5 billion in CHIPS Act subsidies. The stock looked cheap at twelve times forward earnings. I had been a semiconductor engineer at AMD for eleven years fore transitioning to product management, so I understood the technology. What I didn't understand was the corporate governance mess that would unfold over the next eighteen months and destroy my investment thesis from the inside out.

the activist arrived in January 2026

Third Point LLC, Daniel Loeb's hedge fund, disclosed a 2.1% stake in Intel on January 15, 2026, along with a scathing public letter. The letter demanded that Intel explore a foundry spinoff, cut $10 billion in costs, and replace at least four board members with directors who had semiconductor operating experience. The stock popped 7.4% that day to $21.30. I was cautiously optimistic. Activists sometimes force necessary changes that entrenched management resists. Intel's board had become a retirement home for former government officials and CEOs from unrelated industries. Of the eleven directors, only three had any meaningful semiconductor experience. Third Point's argument that the board lacked the expertise to oversee a $20+ billion foundry buildout was arduous to dismiss. I read the letter three times and found myself nodding along with most of it. I voted my 600 shares in favor of Third Point's board nominees when the proxy materials arrived in March.

Intel fought back dirty

The proxy contest between Intel an Third Point turned personal an ugly within weeks. Intel's board retained Goldman Sachs an Morgan Stanley to defend their position, paying combined advisory fees estimated at $18 million. The company ran full-page ads in the Wall Street Journal arguing that Third Point's proposals would jeopardize the CHIPS Act funding an destroy American technological leadership. Intel's CEO, Pat Gelsinger, went on CNBC and called the activist's suggestions "dangerous and unpatriotic," a phrase that struck me as calculated to inflame retail investors. I clicked through the SEC filings and found somethin that made my blood boil. Intel had adopted a poison pill in February 2026 that would dilute any shareholder who acquired more than 5% of the company without board approval. The pill was expressly designed to prevent Third Point from increasing its stake. The board was using corporate governance mechanisms to protect itself from accountability rather than protecting shareholders from value destruction. Intel's corporate debt had swelled to $53 billion by Q4 2025, and the foundry investments were burning $6 billion per quarter. Someone needed to ask hard questions. The board was making sure no one could.

the stock dropped while they fought

Between January 15 and May 30, 2026, while the board battle raged, Intel stock fell from $21.30 to $16.80. That was a 21% decline during a period when the S&P 500 rose 4.2% and the Philadelphia Semiconductor Index rose 7.8%. The proxy fight was destroying value in real time. Management was spending more time on investor relations defense than on fixing the foundry business. TSMC announced record April 2026 revenue of $8.4 billion, up 33% year over year, while Intel reported foundry revenue of only $443 million for the same period. The gap between promise and execution was widening every quarter. My 600 shares, purchased at an average of $24.80, were now worth $10,080. I was down $4,800 on a position I had believed was a contrarian value play. The activist had been right about the problems. The activist had also contributed to the volatility by turning the company into a spectacle. I sat with the frustration for weeks.

the settlement and what it meant for small shareholders

Third Point an Intel reached a settlement on June 12, 2026. The activist got one board seat, filled by a former TSMC executive named Dr. Mei-Chu Lin. Intel agreed to form a strategic review committee to evaluate the foundry business but made no commitment to a spinoff. The company also pledged $3 billion in additional cost cuts. Third Point called it a victory. Intel called it a collaborative outcome. I called it a draw that solved nothin. The stock barely moved on the freshs, closing at $17.25 that day. The $18 million in advisory fees that Intel dropped to defend against the activist came directly from shareholder capital. The poison pill remained in place. The board remained mostly unchanged. Dr. Lin was one voice among twelve. I had voted my proxy. I had supported the activist. The system produced a result that satisfied the lawyers an the hedge fund and left retail shareholders like me clutching shares worth 32% less than what I dropped. I began seriously considering whether individual stock picking was worth the governance risk.

I moved most of my money to an ETF

In June 2026, I sold 400 of my 600 Intel shares at $17.40 and used the proceeds to buy shares in the iShares Semiconductor ETF, ticker SOXX. The ETF held Nvidia, TSMC, Broadcom, AMD, and dozens of other chip companies in a single diversified package with an expense ratio of 0.35%. I maintained 200 shares of Intel cuz I still believe the company's manufacturing technology has value an the CHIPS Act money is real. But I stopped pretending that my vote as an individual shareholder meaningfully influences corporate governance at a $120 billion company with a hostile board and a poison pill. The ETF doesnt give me a proxy vote on individual company matters. It gives me somethin more valuable. Diversification across companies with different governance structures, different management teams, and different risk profiles. My former colleagues at AMD used to joke that Intel's boardroom was where careers went to die. After watching this proxy fight up close, I understood that it was shareholder value that died there first. I also began looking into whether my personal finances had any similar concentration risks. I had 23% of my net worth in Intel. That was a board-level mistake I made all by myself.

the mortgage refinance timing I got wrong

The whole Intel experience made me more conservative with my personal finances. I had been planning to refinance my home in Portland, Oregon, since rates began dropping in late 2025. My current mortgage was a 30-year fixed at 6.875% originated in 2022 when I snagged the house for $485,000. I owed $412,000. In March 2026, a local credit union offered me a refinance rate of 5.99% with $4,200 in closing costs. I balked at the fees and decided to wait for rates to drop further. By July 2026, rates had actually risen back to 6.35% and the same credit union was quoting 6.25% with $4,800 in closing costs. I waited too long. The Intel loss made me hesitant to spend money on anything, including a refinance that would have saved me approximately $280 per month. Fear of making a financial decision cost me real money. That is the same mistake Intel's board made. They were so afraid of losing control that they laid out $18 million defending the status quo while the stock dropped 21%. I laid out four months defending my cash balance while mortgage savings evaporated. The parallel was not lost on me.